Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 10—October 2021
Research

Bloodstream Infection Risk, Incidence, and Deaths for Hospitalized Patients during Coronavirus Disease Pandemic

Bhavarth S. ShuklaComments to Author , Prem R. Warde, Eric Knott, Sebastian Arenas, Darryl Pronty, Reinaldo Ramirez, Arely Rego, Miriam Levy, Martin Zak, Dipen J. Parekh, Tanira Ferreira, and Hayley B. Gershengorn
Author affiliations: University of Miami Health System, Miami, Florida, USA (B.S. Shukla, P.R. Warde, S. Arenas, D. Pronty, R. Ramirez, A. Rego, M. Levy, D.J. Parekh, T. Ferreira, H.B. Gershengorn); University of Miami Miller School of Medicine, Miami (B.S. Shukla, E. Knott, M. Zak, D.J. Parekh, T. Ferreira, H.B. Gershengorn); Albert Einstein College of Medicine, Bronx, New York, USA (H.B. Gershengorn)

Main Article

Table 2

Adjusted association for virus positivity with outcomes for patients during the coronavirus disease pandemic, Miami, Florida, USA, March 25‒October 27, 2020*

Cohort Primary outcome OR/HR (95% CI)
Full
Risk for LCBI† 3.88 (2.70‒5.51)
Time to LCBI‡ 2.35 (1.77‒3.13)
Risk for death,§ adjusted for LCBI 6.68 (4.94‒9.01)
Risk for LCBI-HAI† 5.58 (3.67‒8.43)
Time to LCBI-HAI‡ 2.73 (1.94‒3.85)
Risk for death,§ adjusted for LCBI-HAI
6.64 (4.91‒8.96)
Central line Risk for CLABSI† 5.68 (2.94‒11.1)
Time to CLABSI‡ 2.86 (1.75‒4.65)
Risk for death§ 5.30 (3.68‒7.64)

*All p values were <0.001. BMI, body mass index; CLABSI: central line‒associated bloodstream infection; HR, hazard ratio; ICU, intensive care unit; LCBI, laboratory-confirmed bloodstream infection; OR, odds ratio; SOFA, sequential organ failure assessment. †Modeled with logistic regression including age, sex, race/ethnicity, payer, BMI, no. comorbidities, previous urethral catheter use, previous central line use, previous mechanical ventilation, previous steroid treatment, previous ICU admission, previous dialysis, previous prone positioning, previous remdesivir treatment, tocilizumab treatment, and imputed SOFA score as covariates. OR is reported. ‡Modeled with proportional hazards model including age, sex, race/ethnicity, payer, BMI, no. comorbidities, previous urethral catheter use, previous central line use, previous mechanical ventilation, previous steroid treatment, previous ICU admission, previous dialysis, and imputed SOFA score as covariates. HR is reported. §Modeled with logistic regression including age, sex, race/ethnicity, payer, BMI, no. comorbidities, urethral catheter days, central line days, previous mechanical ventilation days, steroid treatment days, ICU days, dialysis days , imputed SOFA score, and LCBI as covariates; OR is reported.

Main Article

Page created: July 15, 2021
Page updated: September 19, 2021
Page reviewed: September 19, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external